Local
Forced drug switches are burying clinics in paperwork
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: VTDigger

This commentary is by Teresa Fama, a practicing rheumatologist at University of Vermont Health. Vermont and the nation are struggling with how to reduce healthcare costs. Much of the increase is due to prescription drugs and labor, particularly as the latter makes up 65% of UVM Health’s total expenses. To highlight the compounding effect on costs from these two aspects of healthcare, let’s look at Vermont’s Act 193. Vermont’s Act 193 requires pharmacists to dispense the lowest-priced interchangeable biologic medication to patients. These interchangeable biologic medications are biosimilars of the reference product, meaning they are highly similar with no clinically meaningful differences in safety, purity or potency — think similar to “generic.” Act 193 was enacted in 2018 when not many biosimilars were available. For example, Humira, the most prescribed biologic to treat rheumatoid arthritis, had three biosimilars approved in 2018. Today, there are 10.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at VTDigger


